The renal effects of the water-soluble, non-folylpolyglutamate synthetase-dependent thymidylate synthase inhibitor ZD9331 in mice.

Autor: Walton, MI, Mitchell, F, Aherne, GW, Medlow, CJ, Boyle, FT, Jackman, AL, Walton, M I, Aherne, G W, Medlow, C J, Boyle, F T, Jackman, A L

Publikováno v: British Journal of Cancer; Dec1998, Vol. 78 Issue 11, p1457-1463, 7p

Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models.

Autor: Aherne, GW, Ward, E, Lawrence, N, Dobinson, D, Clarke, SJ, Musgrove, H, Sutcliffe, F, Stephens, T, Jackman, AL, Aherne, G W, Clarke, S J, Jackman, A L

Publikováno v: British Journal of Cancer; Jan1998, Vol. 77 Issue 2, p221-226, 6p

Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors

Autor: Martin R. Brown, Kimbell R, Marsham Pr, Wardleworth Jm, F T Boyle, Jackman Al, Laurent Francois Andre Hennequin

Publikováno v: Journal of medicinal chemistry. 42(19)

The synthesis is described of a series of analogues of the potent thymidylate synthase (TS) inhibitor, N-[4-[N-[(3,4-dihydro-2, 7-dimethyl-4-oxo-6-quinazolinyl)methyl]-N-prop-2-ynylamino]-2-f luorob enzoyl]-L-glutamic acid (4, ZM214888), in which the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2098390e62053c52a36116f5de61104c
https://pubmed.ncbi.nlm.nih.gov/10508430

Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.

Autor: Banerji U; Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK., Sain N; Section of Medicine, Haddow Laboratories, The Institute of Cancer Research, Sutton, UK., Sharp SY; Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK., Valenti M; Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK., Asad Y; Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK., Ruddle R; Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK., Raynaud F; Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK., Walton M; Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK., Eccles SA; Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK., Judson I; Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK., Jackman AL; Section of Medicine, Haddow Laboratories, The Institute of Cancer Research, Sutton, UK., Workman P; Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. Paul.Workman@icr.ac.uk.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2018 Nov; Vol. 82 (5), pp. 911-912.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.